COVID-19 Vaccine program, the company said that the new results from a preclinical study of the company’s COVID-19 variant-specific vaccine candidates showed that it increases neutralizing titers against SARS-CoV-2 variants of concern.
To date, the company has delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.The company shared an update on the Phase 3 COVE study of the Moderna COVID-19 Vaccine.